-+ 0.00%
-+ 0.00%
-+ 0.00%

Inovio seeks conditional EU approval for VOCERYQ to treat RRP

PUBT·11/18/2026 13:08:48
Listen to the news
Inovio seeks conditional EU approval for VOCERYQ to treat RRP
  • Inovio submitted a conditional marketing authorization application to the European Medicines Agency for Voceryq in adults with recurrent respiratory papillomatosis.
  • Voceryq received FDA accelerated approval on October 30, 2026, to reduce surgery frequency in adults with the disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH00829) on November 18, 2026, and is solely responsible for the information contained therein.